Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1628
This examiner grants 34% of resolved cases
Chihyi Nmn Lee works in Tech Center 1600 and Art Unit 1628. The examiner has 86 resolved cases with an allowance rate of 33.7 percent. This low rate suggests a challenging environment for applicants. Practitioners should be prepared for a rigorous examination process given the 33.7 percent allowance rate.
The interview lift is 60.8 percent. This is an exceptionally high lift, indicating that interviews are the most effective way to improve the chances of allowance. An interview can nearly double the probability of success compared to the base rate. The 60.8 percent lift is the most critical strategic tool for navigating prosecution in Art Unit 1628.
The median days to allowance is 1294. This duration is standard for Tech Center 1600. Given the low base allowance rate and the high interview lift, practitioners should prioritize direct communication with the examiner. The 1294-day median pendency and 86 resolved cases provide a clear view of the challenges and opportunities in this profile.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18273942 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | Final Rejection | The Regents of the University of Michigan |
| 18003807 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | Non-Final OA | The Cleveland Clinic Foundation |
| 17761902 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | Non-Final OA | NOVARTIS AG |
| 18749726 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | Non-Final OA | United States Government as represented by the Department of Veterans Affairs |
| 18483225 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | Final Rejection | The United States Government as represented by the Department of Veterans Affairs |
| 18330100 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Final Rejection | Xenon Pharmaceuticals Inc. |
| 18210991 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | Final Rejection | Hoffmann-La Roche Inc. |
| 17558402 | Polyphenols as Modulators of Platelet Function | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18794153 | Methods for Treating Traumatic Brain Injury | Non-Final OA | The Government of the United States, as Represented by the Secretary of the Army |
| 17424979 | USE OF MIGALOSTAT IN REDUCING THE RISK OF CEREBROVASCULAR EVENT IN PATIENTS WITH FABRY DISEASE | Final Rejection | Amicus Therapeutics, Inc. |
| 18675614 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR TREATING DEPRESSION | Final Rejection | GH RESEARCH IRELAND LIMITED |
| 18342239 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Non-Final OA | CORCEPT THERAPEUTICS INCORPORATED |
| 18263293 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | Final Rejection | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18141128 | INDUCTION OF IMMUNE TOLERANCE BY USING METHOTREXATE | Final Rejection | Genzyme Corporation |
| 18253061 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | Final Rejection | ELANCO TIERGESUNDHEIT AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy